Seres Therapeutics, a US-based bacterial infection treatment developer backed by food and nutrition product maker Nestlé and health researcher Mayo Clinic, priced its $134m initial public offering yesterday.
The company is issuing more than 7.4 million shares priced at $18 each, above the $15 to $17 range it set last week. It will begin trading on Nasdaq later today.
Seres will spend $25m of the IPO proceeds to complete a Phase 2 clinical study for SER-109, its lead product candidate,…
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
